NCT01451125已完成2 期
A Phase 2 Study to Evaluate and Compare the Efficacy of Injections of Ex Vivo Expanded Cultured Occipital Autologous Dermal and Epidermal Cells vs. Dermal Cells Into the Hair Loss Area of the Scalp of Subjects and Synergy With Application of Topical Minoxidil
Aderans Research Institute5 个研究点 分布在 1 个国家目标入组 43 人开始时间: 2010年5月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 43
- 试验地点
- 5
- 主要终点
- Change from baseline in hair number
研究概览
简要总结
The purpose of the study is to evaluate the ability of injections of Ji Gami(TM) or Ji Gami(TM) DO in combination with minoxidil to induce hair growth in male and female subjects with hair loss.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female volunteers 18 to 65 years old, inclusive
- •Hair loss consistent with ≥ Grade III-Vertex, IV, VA, V, and VI, based on Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of the vertex circle.
- •Have no clinically significant disease or abnormal laboratory results taken at the screening visit.
- •Agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, finasteride or dutasteride during the course of this study (other than minoxidil as required in this study).
排除标准
- •Known sensitivity to DMEM/F-12 or any component of the study material.
- •Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin sulfate.
- •Subjects who have used any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening (with the exception of minoxidil).
- •A history of drug or alcohol abuse within 1 year of study enrollment.
- •Clinically significant medical or psychiatric illness currently or within 30 days of study screening as determined by the investigator.
- •Any clinically significant abnormal laboratory parameters.
- •A positive result at screening for human immunodeficiency virus (HIV 1 or 2), Hepatitis B or C, HTLV I/II.
- •Dermatologic condition in donation or treatment area.
- •Prior surgery in the treatment and/or study areas.
- •Insufficient hair or scarring in the donor area that might impact cell growth.
- •Any disease or condition (medical or surgical) that, in the opinion of the investigator, might compromise hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system function; or any condition that would place the subject at increased risk.
- •Hypersensitivity to minoxidil or the ingredients in the topical solution or foam formulations.
结局指标
主要结局
Change from baseline in hair number
时间窗: 51 weeks post-injection
Change from baseline in hair width
时间窗: 51 weeks post-injection
Time course of any treatment benefit
时间窗: 51 weeks post-injection
次要结局
- Effect of minoxidil(Week 12, 18, 24, 33 and 51 post-injection)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)Male Pattern BaldnessFemale Pattern BaldnessAndrogenetic AlopeciaNCT01451138Aderans Research Institute40
已完成
2 期
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542)Male Pattern BaldnessFemale Pattern BaldnessAndrogenetic AlopeciaNCT01451151Aderans Research Institute33
已完成
2 期
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)Male Pattern BaldnessFemale Pattern BaldnessAndrogenetic AlopeciaNCT01451177Aderans Research Institute43
已完成
2 期
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013)Male Pattern BaldnessFemale Pattern BaldnessAndrogenetic AlopeciaNCT01451073Aderans Research Institute33
已完成
2 期
A Study to Assess Dose-Response, Efficacy (Immunogenicity) and the Safety of GC1109AnthraxNCT01624532Green Cross Corporation240